J.R. DeVita
Vice President of Corporate Development and Investor Relations
Replay available
Nuvation Bio Inc. (NUVB) Q1 2026 Earnings Call
Nuvation Bio Inc. (NYSE: NUVB) Q1 2026 earnings conference call, held 2026-05-04. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. David Hung
Founder, President and Chief Executive Officer
Colleen Sjogren
Chief Commercial Officer
Philippe Sauvage
Chief Financial Officer
Farzin Haque
Analyst, Jefferies
Leonid Timashev
Analyst, RBC Capital Markets
Gregory Renza
Analyst, Truist Securities
Kaveri Pullman
Analyst, Clear Street
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Nuvation Bio Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.300 Hello and welcome to NovationBio's first quarter 2026 financial 00:00:05.300 -- 00:00:10.529 results and corporate update call. Today's call is being recorded and 00:00:10.529 -- 00:00:14.074 a replay will be available on the company's website. 00:00:14.074 -- 00:00:18.161 All participants are currently in a listen only mode. 00:00:18.161 -- 00:00:22.188 A brief question and answer session will follow the prepared remarks. 00:00:22.188 -- 00:00:25.136 Now, I'd like to turn the call over to J.R. 00:00:25.136 -- 00:00:30.591 DeVita, Vice President of Corporate Development and Investor Relations at Nuvation 00:00:30.591 -- 00:00:34.075 Bio. Please go ahead. 00:00:34.903 -- 00:00:40.023 Thank you, and good afternoon, everyone. Earlier today, we issued a press release 00:00:40.023 -- 00:00:45.557 summarizing our financial results for the quarter ending March 31st, 2026, 00:00:45.557 -- 00:00:50.671 and provided a business update. The press release is available on the investor section 00:00:50.671 -- 00:00:54.154 of our website at nuvationbio.com. 00:00:55.111 -- 00:01:00.238 Today's call includes forward-looking statements, including statements about the therapeutic 00:01:00.238 -- 00:01:04.224 and commercial potential of Ibtrozi and Safucitinib, 00:01:04.224 -- 00:01:08.930 our plans for Safucitinib development and future data presentations, 00:01:08.930 -- 00:01:14.097 the components of our anticipated product revenue, expected milestone payments, 00:01:14.097 -- 00:01:16.593 and our cash runway. 00:01:16.593 -- 00:01:22.642 Because such statements deal with future events and are subject to many risks and uncertainties, 00:01:22.642 -- 00:01:27.710 actual results may differ materially from those in the forward-looking statements. 00:0...